SCHEMBL3872157

SCHEMBL3872157

CCN(CC)C(=O)c1cccc(CN(C)S(=O)(=O)c2cc3ccccc3s2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.45
SQLE Q14534 1/20 0.44
LMNA P02545 4/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
HPGD P15428 3/20 0.41
TDP1 Q9NUW8 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.40
KMT2A Q03164 2/20 0.40
HDAC4 P56524 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
ALDH1A1 P00352 1/20 0.39
AOC3 Q16853 1/20 0.39
TSHR P16473 1/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3886237 0.87 TRPM8 (0.49) SQLELMNASMN1; SMN2HPGDTRPM8
SCHEMBL3879707 0.84 RAB9A (0.53) SQLELMNANPC1RAB9ASMN1; SMN2
SCHEMBL3874108 0.81 HSD11B1 (0.47) PPARGLMNANPC1RAB9ASMN1; SMN2
SCHEMBL3875049 0.81 PPARG (0.48) PPARGLMNANPC1RAB9ASMN1; SMN2
SCHEMBL3887293 0.79 MAPT (0.49) LMNANPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL3872649 0.78 ALDH1A1 (0.49) LMNANPC1RAB9ASMN1; SMN2HPGD
SCHEMBL3876863 0.78 NR1H4 (0.49) PPARGLMNARAB9ASMN1; SMN2ALDH1A1
SCHEMBL3872970 0.77 ROCK2 (0.45) PPARGLMNARAB9ASMN1; SMN2ALDH1A1
SCHEMBL3882723 0.77 ALDH1A1 (0.51) LMNANPC1SMN1; SMN2KMT2AHDAC6
SCHEMBL3880937 0.77 RAB9A (0.52) PPARGLMNARAB9ASMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1814846-B1 11BETA-HSD1 INHIBITORS EVOTEC AG (DE) 2009-04-08 EP disclosed
US-20090069323-A1 11beta-hsdi inhibitors EVOTEC AG (DE) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069323-A1 11beta-hsdi inhibitors HSD3B1, HSD3B2, HSD11B1 PPARG 2392/4885SQLE 590/4885LMNA 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.